Tocqueville Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
Other funds holding SRPT
ACA
AIM
Tocqueville Asset Management's SRPT Position: Q1 2021 in Review
Tocqueville Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 2,000 shares — an estimated $341K sold.
Tocqueville Asset Management first reported a position in SRPT in Q2 2013 and held it in 17 quarters. The position peaked at $10.5M in Q3 2018. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.
- Tocqueville Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
- Tocqueville Asset Management sold 2,000 Sarepta Therapeutics shares in Q1 2021, an estimated $341K.
- Tocqueville Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 17 quarters.
- Tocqueville Asset Management's Sarepta Therapeutics position peaked at $10.5M in Q3 2018.
- 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.
Based on Tocqueville Asset Management's 13F filing for Q1 2021, filed 17 May 2021.